Troxacitabine-based therapy of refractory leukemia

References

• Estey EH, Thall PF, Pierce S et al. Randomized phase II study of fludarabine + cytosine arabinoside + idarubicin ± all-trans retinoic acid ± granulocyte colony-stimulating factor in poor prognosis newly diagnosed acute myeloid leukemia and myelodysplastic syndrome. B1ixd93, 478-2484(1999).
   Google Scholar
• Burnett AK. Tailoring the treatment of acute myeloid leukemia. Curn Opin. Hematot 6, 247–252 (1999).
   PubMedGoogle Scholar
• McCarthy AJ, Pitcher LA, Hann IM et al. FLAG (fludarabine, high-dose cytarabine and G-CSF) for refractory and high-risk relapsed acute leukemia in children. Med. Pediatr. Oncol. 32, 411–415 (1999).
   PubMedGoogle Scholar
• Keating MJ. Leukemia: a model for drug development. Clin. Cancer Res. 3, 2598–2604 (1997).
   PubMedGoogle Scholar
• Mansour TS, Jin H, Wang W et al. Anti- human immunodeficiency virus and anti-hepatitis-B virus activities and andcities of the enantiomers of 2'-deoxy-3'-oxa-4'-thiocytidine and their 5-fluoro analogues in vitro.j Med. Chem. 38, 1–4 (1995).
   Google Scholar
• Balzaririi J, Wedgwood 0, Kruining J et al Anti-HIV and anti-HBV activity and resistance profile of 2, 3'-dideoxy- 3'-thiacytidine (3TC) and its arylphosphoramidate derivative CF 1109. Biochem. Biophys. Res. Commun. 225, 363–369 (1996).
   Google Scholar
• Mar EC, Chu CK, Lin JC. Some nucleosideanalogs with anti-human immunodeficiency virus activity inhibit replication of Epstein-Barr virus. Antiviral Res. 28, 1–11 (1995).
   Google Scholar
• Coates JA, Cammack N, Jenkinson HJ et al. (-)-2'-deoxy-3'-thiacytidine is a potent, highly selective inhibitor of human immunodeficiency virus type 1 and type 2 replication in vitro. Antimicrob. Agents Chemothen 36, 733–739 (1992).
   Google Scholar
• Grove KL, Guo X, Liu SH et al. Anticancer activity of13-L-dioxolane-cytidine, a novel nucleoside analogue with the unnatural L configuration. Cancer Res. 55, 3008–3011 (1995)•
   Google Scholar
• Grove KL, Cheng YC. Uptake andmetabolism of the new anticancer compound 13-L-(-)- dioxolane-cytidine in human prostate carcinoma DU-145 cells. Cancer Res. 56, 4187–4191 (1996).
   PubMed Web of Science ®Google Scholar
• Siu LL, Attardo G, Izbicka E et al. Activity of (-)-2'-deoxy-3'-oxacytidine (BCH-4556) against human tumor colony-forming units. Ann. Oncol. 9, 885–891 (1998).
   Google Scholar
• Kadhim SA, Bowlin TL, Waud WR et al. Potent antitumor activity of a novel nucleoside analogue, BCH-4556 (13-L-dioxolane-cytidine), in human renal cell carcinoma xenograft tumor models. Cancer Res. 57, 4803–4810 (1997).
   PubMed Web of Science ®Google Scholar
• Kukhanova M, Liu SH, Mozzherin D et al. L- and D-enantiomers of 2',3'-dideoxycytidine 5'-triphosphate analogs as substrates for human DNA polymerases. Implications for the mechanism of toxicity. J. Biol. Chem. 270, 23055–23059 (1995).
   Google Scholar
• Grant S. Ara-C: cellular and molecularpharmacology. Adv. Cancer Res. 72, 197–233 (1998).
   PubMed Web of Science ®Google Scholar
• Chiba P, Than T, Szekeres T et aZ Concordant changes of pyrimidine metabolism in blasts of two cases of acute myeloid leukemia after repeated treatment with ara-C in vivo. Leukemia 4, 761–765 (1990).
   PubMed Web of Science ®Google Scholar
• Harris AL, Grahame-Smith DG, Potter CG et d Cytosine arabinoside deamination in human leukaemic myeloblasts and resistance to cytosine arabinoside therapy. Clin. Sci (Cokh) 60, 191–198 (1981).
   PubMedGoogle Scholar
• Flasshove M, Frings W, Schroder JK et al. Transfer of the cytidine deaminase cDNA into hematopoietic cells. Leuk. Res. 23, 1047–1053 (1999).
   PubMed Web of Science ®Google Scholar
• Giles FJ, Cortes JE, Baker SD et al. Troxacitabine, a novel dioxolane nucleoside analog, has activity in patients with advanced leukemia.' Clin. OncoZ 19, 762–771, (2001).
   PubMed Web of Science ®Google Scholar
• •Phase I study in patients with refractory leukemia showing significant single-agent activity.
   Google Scholar
• Giles FJ, Cortes JE, Garcia-Manero Get al. Troxatyl plus topotecan, ara-C, or idarubicin in patients with leukemia: A randomized Phase I/II study [abstract]. Blood290a (2001).
   Google Scholar
• Giles FJ, Garcia-Manero G, Cortes JE et al. Phase II study of Troxacitabine, a novel dioxolane nucleoside analog, in patients with refractory leukemia.' Clin. Oncol. 20, 656–664 (2002)
   Google Scholar
• •Documents significant single-agent activity in patients with CMIL-BP.
   Google Scholar
• Gourdeau H, Bibeau L, Ouellet F et d Comparative study of a novel nudeoside analogue (Troxatyl, troxacitabine, BCH-4556) and AraC against leukemic human tumor xenografts expressing high or low cytidine deaminase activity. Cancer Chemothen Pharmacd 47,236–240 (2001).
   PubMed Web of Science ®Google Scholar
• ••Troxacitabine may have a metabolic advantage in leukemias resistant to ara-C because of high cytidine deatninase activity.
   Google Scholar
• Gourdeau H, Clarke ML, Ouellet F et al. Mechanisms of uptake and resistance to troxacitabine, a novel deoxycytidine nucleoside analogue, in human leukemic and solid tumor cell lines. Cancer Res. 61, 7217–7224 (2001).
   PubMed Web of Science ®Google Scholar
• ••In vitro data highlighting potentialadvantage of troxacitabine in terms of cellular uptake mechanisms.
   Google Scholar
• Moore LE, Boudinot FD, Chu CK. Preclinical pharmacokinetics of beta-L-dioxolane-cytidine, a novel anticancer agent, in rats. Cancer Chemother. Pharmacot 39, 532–536 (1997).
   Google Scholar
• Kukhanova M, Liu TW, Pelicano H et al. Excision of I3-D- and I3-L-nucleotide analogs from DNA by p53 protein. Nucleosides Nucleotides Nucleic Acids 19, 435 116 (2000)
   Google Scholar
• Pelicano H, Kukhanova M, Cheng YC. Excision of I3-D- and I3-L-nucleotide analogs from DNA by the human cytosolic 3'-to-5 exonuclease. MoZ Pharmacot 57, 1051–1055 (2000).
   Google Scholar
• Skalski V, Chang CN, Dutschman G et aZ The biochemical basis for the differential anti-human immunodeficiency virus activity of two cis enantiomers of 2',3'-dideoxy-3'-thiacytidine. J. Biol. Chem. 268, 23234–23238 (1993).
   Google Scholar
• Skalski V, Liu SH, Cheng YC. Removal of anti-human immunodeficiency virus 2',3'-dideoxynucleoside monophosphates from DNA by a novel human cytosolic 3' to 5' exonudease. Biochem. Pharmacol. 50, 815–821 (1995).
   Google Scholar
• Perrino FW, Miller H, Ealey KA. Identification of a 3' to 5'-exonuclease that removes cytosine arabinoside monophosphate from 3' termini of DNA. J. Biol. Chem. 269, 16357–16363 (1994).
   Google Scholar
• Perrino FW, Mazur DJ, Ward H et al. Exonucleases and the incorporation of aranucleotides into DNA. Cell Biochem. Biophys. 30, 331–352 (1999).
   PubMedGoogle Scholar
• Mazur DJ, Perrino FW Identification and expression of the TREX1 and TREX2 cDNA sequences encoding mammalian 3' to 5' exonucleases. J. Biol. Chem. 274, 19655–19660 (1999).
   Google Scholar
• Chou KM, Kukhanova M, Cheng YC. A novel action of human Apurinic/ Apyrimidinic endonuclease. Excision of L-configuration deoxyribonucleoside analogs from the 3' termini of DNA.' Biol. Chem. 275, 31009–31015 (2000).
   Google Scholar
• Gati WP Paterson AR, Belch AR et al. Es nucleoside transporter content of acute leukemia cells: role in cell sensitivity to cytarabine (araC). Leuk Lymphoma 32, 45–54 (1998).
   PubMedGoogle Scholar
• Belanger K, Moore M, Siu L et at A phase I study of the L-nucleoside analogue I3-L-dioxolan-cytidine (BCH-4556) given as a 30 minute infusion every 21 days. Proc. Am. Soc. Clin. °mot 18, 197a, (1999)
   Google Scholar
• Baker SD, Stephenson Jr. J, Goetz A et id Determinants affecting I3-L-dioxolan-cytidine (BCH-4556) exposure and relationship with toxicity in Phase 1 trials. Proc. Ai z Soc. Clin. OncoZ 18, 197a (1999) (Abstract 758).
   Google Scholar
• Canova A, Yee L, Baker SD et aZ A phase 1 and pharmacokinetic study of beta-L-dioxolan-cytidine (BCH-4556) administered weekly for three weeks every 28 days. Proc. Am. Soc. Clin. °mot 18, 197a, (1999).
   Google Scholar
• de Bono JS, Stephenson J, Jr., Baker SD et al. Troxacitabine, an L-stereoisomeric nucleoside analog, on a five-times-daily schedule: a phase I and pharmacokinetic study in patients with advanced solid malignancies. J. Clin. °mot 20, 96–109 (2002).
   Google Scholar
• •Comprehensive Phase I and pharmacokinetic study in patients with solid tumors.
   Google Scholar
• Vukelja SJ, Lombardo FA, James WD et al. Pyridoxine for the palmar-plantar erythrodysesthesia syndrome. Ann. Intern. Med. 111, 688–689 (1989).
   PubMed Web of Science ®Google Scholar
• Lopez AM, Wallace L, Don RT et al. Topical DMSO treatment for pegylated liposomal doxorubicin-induced palmar-plantar erythrodysesthesia. Cancer Chemother. Pharmaca 44, 303–306 (1999).
   PubMed Web of Science ®Google Scholar